Antibody–Drug Conjugates for Cancer Therapy

Antibody–Drug Conjugates for Cancer Therapy

Show other versions (1)

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity t...

Full description

Bibliographic Details
Main Authors: Umbreen Hafeez, Sagun Parakh, Hui K Gan, Andrew M Scott
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Molecules
Subjects:
antibody–drug conjugate
ADC
monoclonal antibody
cytotoxic payload
linkers, cancer
molecular imaging.
Online Access:https://www.mdpi.com/1420-3049/25/20/4764
id doaj-fd2c927ee8a84b3fa0e7808f9755a84a
record_format Article
spelling doaj-fd2c927ee8a84b3fa0e7808f9755a84a2020-11-25T03:55:40ZengMDPI AGMolecules1420-30492020-10-01254764476410.3390/molecules25204764Antibody–Drug Conjugates for Cancer TherapyUmbreen Hafeez0Sagun Parakh1Hui K Gan2Andrew M Scott3Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia, <email>umbreen.hafeez@onjcri.org.au</email> (U.H.)Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia, <email>umbreen.hafeez@onjcri.org.au</email> (U.H.)Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia, <email>umbreen.hafeez@onjcri.org.au</email> (U.H.)Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia, <email>umbreen.hafeez@onjcri.org.au</email> (U.H.)Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.https://www.mdpi.com/1420-3049/25/20/4764antibody–drug conjugateADCmonoclonal antibodycytotoxic payloadlinkers, cancermolecular imaging.
collection DOAJ
language English
format Article
sources DOAJ
author Umbreen Hafeez
Sagun Parakh
Hui K Gan
Andrew M Scott
spellingShingle Umbreen Hafeez
Sagun Parakh
Hui K Gan
Andrew M Scott
Antibody–Drug Conjugates for Cancer Therapy
Molecules
antibody–drug conjugate
ADC
monoclonal antibody
cytotoxic payload
linkers, cancer
molecular imaging.
author_facet Umbreen Hafeez
Sagun Parakh
Hui K Gan
Andrew M Scott
author_sort Umbreen Hafeez
title Antibody–Drug Conjugates for Cancer Therapy
title_short Antibody–Drug Conjugates for Cancer Therapy
title_full Antibody–Drug Conjugates for Cancer Therapy
title_fullStr Antibody–Drug Conjugates for Cancer Therapy
title_full_unstemmed Antibody–Drug Conjugates for Cancer Therapy
title_sort antibody–drug conjugates for cancer therapy
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2020-10-01
description Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.
topic antibody–drug conjugate
ADC
monoclonal antibody
cytotoxic payload
linkers, cancer
molecular imaging.
url https://www.mdpi.com/1420-3049/25/20/4764
work_keys_str_mv AT umbreenhafeez antibodydrugconjugatesforcancertherapy
AT sagunparakh antibodydrugconjugatesforcancertherapy
AT huikgan antibodydrugconjugatesforcancertherapy
AT andrewmscott antibodydrugconjugatesforcancertherapy
_version_ 1724468837590499328

Similar Items